{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:02:05Z","timestamp":1780117325284,"version":"3.54.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.radonc.2025.111112","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:29:28Z","timestamp":1756308568000},"page":"111112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["MUlticentre REtrospective comparison of definitive EBRT with or without HDR BRAchytherapy boost in patients with locally-advanced prostate cancer and regional lymph NOde metastases (MUREBRANO) \u2013 A propensity score matched analysis"],"prefix":"10.1016","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4962-3028","authenticated-orcid":false,"given":"Mateusz","family":"Bilski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Lelek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2608-1959","authenticated-orcid":false,"given":"Magdalena","family":"Stankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4375-0827","authenticated-orcid":false,"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Burchardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9933-3646","authenticated-orcid":false,"given":"Adam","family":"Kluska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7390-9165","authenticated-orcid":false,"given":"Aleksandra","family":"Napieralska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9940-0204","authenticated-orcid":false,"given":"Andrzej","family":"Kukie\u0142ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8375-5289","authenticated-orcid":false,"given":"Pawe\u0142","family":"Cisek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Konat-B\u0105ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2543-8370","authenticated-orcid":false,"given":"Rafa\u0142","family":"Stando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Dec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Piliszczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Matys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Bajon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9124-1509","authenticated-orcid":false,"given":"Maciej","family":"Trojanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-8866","authenticated-orcid":false,"given":"Matthias","family":"Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-5839","authenticated-orcid":false,"given":"Alfonso","family":"Gomez-Iturriaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6354-5030","authenticated-orcid":false,"given":"Adam","family":"Chiche\u0142","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Wojcieszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3062-8395","authenticated-orcid":false,"given":"Artur J.","family":"Chyrek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111112_b0005","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.111112_b0010","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Prostate cancer. Published 2024. Accessed April 4, 2025 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"10.1016\/j.radonc.2025.111112_b0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.111112_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1050317","article-title":"Evaluation of the role of local therapy in patients with cN1M0 prostate cancer: a population-based study from the SEER database","volume":"12","author":"Qi","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0025","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.euo.2019.02.001","article-title":"A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer","volume":"2","author":"Ventimiglia","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0030","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/pros.24609","article-title":"Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate\u2010specific antigen concentrations","volume":"83","author":"\u015alusarczyk","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.radonc.2025.111112_b0035","unstructured":"European association of urology. Prostate cancer. Published 2025. Accessed April 4, 2025 https:\/\/uroweb.org\/guidelines\/prostate-cancer 6.3.4.4 str. 86 (full-text guidelines)."},{"key":"10.1016\/j.radonc.2025.111112_b0040","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0045","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.brachy.2024.06.002","article-title":"Brachytherapy based microboosting to the dominant intraprostatic lesion in prostate cancer: a systematic review on treatment outcomes and toxicities","volume":"23","author":"Kazemi","year":"2024","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111112_b0050","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.euo.2024.01.008","article-title":"Prostate virtual high-dose-rate brachytherapy boost: 5-year results from the PROMETHEUS prospective multicentre trial","volume":"7","author":"Wegener","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0055","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2024.03.009","article-title":"Simultaneous focal boost with stereotactic radiation therapy for localized intermediate- to high-risk prostate cancer: primary outcomes of the SPARC phase 2 trial","volume":"120","author":"Yasar","year":"2024","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0065","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0070","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5114\/jcb.2024.146671","article-title":"Prostate brachytherapy boost: long-term results of protocol-based treatment of patients with non-metastatic prostate cancer","volume":"16","author":"Schweizer","year":"2024","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111112_b0075","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2019.11.415","article-title":"Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR trial","volume":"106","author":"Joseph","year":"2020","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109632","article-title":"Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients","volume":"183","author":"Miszczyk","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0085","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.brachy.2020.05.007","article-title":"Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer","volume":"19","author":"Fischer-Valuck","year":"2020","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111112_b0090","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.euo.2024.04.004","article-title":"The state of intermediate clinical endpoints as surrogates for overall survival in prostate cancer in 2024","volume":"7","author":"Miszczyk","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0095","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0100","series-title":"RStudio: Integrated Development Environment for R","author":"RStudio Team","year":"2024"},{"key":"10.1016\/j.radonc.2025.111112_b0105","series-title":"R: a Language and Environment for Statistical Computing","author":"R Core Team","year":"2024"},{"key":"10.1016\/j.radonc.2025.111112_b0110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13073-024-01302-x","article-title":"Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole-genome sequencing with histopathological features","volume":"16","author":"Rao","year":"2024","journal-title":"Genome Med"},{"key":"10.1016\/j.radonc.2025.111112_b0115","article-title":"Virchow\u2019s node as the initial presentation of metastatic prostate cancer: a case series of a common cancer in uncommon location","volume":"2020(11)","author":"Mbwambo","year":"2020","journal-title":"J Surg Case Rep"},{"key":"10.1016\/j.radonc.2025.111112_b0120","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1038\/s41467-024-48629-y","article-title":"Integrative multi-region molecular profiling of primary prostate cancer in men with synchronous lymph node metastasis","volume":"15","author":"Singhal","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2025.111112_b0125","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1007\/s10147-021-02023-6","article-title":"The effectiveness of high-dose-rate brachytherapy with external beam radiotherapy for clinically locally advanced and node-positive prostate cancer: long-term results of a retrospective study","volume":"26","author":"Makino","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0130","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00066-023-02129-y","article-title":"Whole-pelvic irradiation with boost to involved nodes and prostate in node-positive prostate cancer\u2014long-term data from the prospective PLATIN-2 trial","volume":"200","author":"Fink","year":"2024","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2025.111112_b0135","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2021.06.010","article-title":"OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer","volume":"80","author":"Supiot","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.111112_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2022.04.020","article-title":"Oligorecurrent nodal prostate cancer: radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial","volume":"172","author":"Achard","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0145","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clon.2020.10.019","article-title":"Safety and efficacy of ultra-hypofractionation in node-positive prostate cancer","volume":"33","author":"Telkhade","year":"2021","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0150","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0155","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.radonc.2019.02.018","article-title":"Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study","volume":"135","author":"B\u00fcchser","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0160","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3390\/cancers11060860","article-title":"The 6th R of radiobiology: reactivation of anti-tumor immune response","volume":"11","author":"Boustani","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2025.111112_b0165","doi-asserted-by":"crossref","first-page":"458","DOI":"10.5114\/jcb.2021.108601","article-title":"Radioimmunotherapy: future prospects from the perspective of brachytherapy","volume":"13","author":"Fleischmann","year":"2021","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111112_b0170","doi-asserted-by":"crossref","unstructured":"Kubo M, Satoh T, Ishiyama H, et al. Enhanced activated T\u00ef\u00bf\u00bdcell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy. Oncol Rep. Published online November 13, 2017. doi:10.3892\/or.2017.6095.","DOI":"10.3892\/or.2017.6095"},{"key":"10.1016\/j.radonc.2025.111112_b0175","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.ijrobp.2024.07.094","article-title":"Combination of nivolumab immunotherapy with radiation therapy and androgen deprivation therapy in the management of gleason group 5 prostate cancer: final analysis of a phase 2 trial","volume":"120","author":"Bryant","year":"2024","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0180","article-title":"Abstract CT157: combination of nivolumab with standard of care in the management of grade group 5 prostate cancer: Interim analysis of a phase II trial","volume":"83(8_Supplement)","author":"Bryant","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2025.111112_b0185","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.111112_b0190","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The lancet commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.111112_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euo.2021.08.001","volume":"5","author":"Stabile","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2025.111112_b0200","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2016.06.046","article-title":"Clinical outcomes for patients with gleason score 9\u201310 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional comparative analysis","volume":"71","author":"Kishan","year":"2017","journal-title":"Eur Urol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402504616X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402504616X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:22:23Z","timestamp":1780114943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402504616X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":40,"alternative-id":["S016781402504616X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111112","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MUlticentre REtrospective comparison of definitive EBRT with or without HDR BRAchytherapy boost in patients with locally-advanced prostate cancer and regional lymph NOde metastases (MUREBRANO) \u2013 A propensity score matched analysis","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111112"}}